Header Logo

COYA TAPIA

TitleAssistant Professor
InstitutionMD Anderson
DepartmentTranslational Molecular Pathology
Address1515 Holcombe Blvd.
Houston TX 77030
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Pairawan S, Akcakanat A, Kopetz S, Tapia C, Zheng X, Chen H, Ha MJ, Rizvi Y, Holla V, Wang J, Evans KW, Zhao M, Busaidy N, Fang B, Roth JA, Dumbrava EI, Meric-Bernstam F. Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Sci Rep. 2022 01 24; 12(1):1248. PMID: 35075200; PMCID: PMC8786858.
      Citations:    Fields:    Translation:HumansAnimalsCells
    2. Evans KW, Yuca E, Scott SS, Zhao M, Paez Arango N, Cruz Pico CX, Saridogan T, Shariati M, Class CA, Bristow CA, Vellano CP, Zheng X, Gonzalez-Angulo AM, Su X, Tapia C, Chen K, Akcakanat A, Lim B, Tripathy D, Yap TA, Francesco MED, Draetta GF, Jones P, Heffernan TP, Marszalek JR, Meric-Bernstam F. Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer. Cancer Res. 2021 11 01; 81(21):5572-5581. PMID: 34518211; PMCID: PMC8563442.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    3. Shariati M, Evans KW, Zheng X, Bristow CA, Ng PK, Rizvi YQ, Tapia C, Yang F, Carugo A, Heffernan TP, Peoples MD, Tripathy D, Meric-Bernstam F. Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations. Oncogene. 2021 07; 40(26):4425-4439. PMID: 34108622.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    4. Xu M, Tapia C, Hajjar J, Sabir S, Colen R, Nagarajan P, Aung PP, Gong J, Rodon J, Fu S, Stephen B, Roy-Chowdhuri S, Le H, Yang V, Zarifa A, Abdelsalam ME, Jhingran A, Javle M, Pant S, Carter B, Milton DR, Sun R, Karp DD, Koay EJ, Yang Y, Wistuba II, Hwu P, Meric-Bernstam F, Naing A. Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. J Immunother Precis Oncol. 2021 May; 4(2):45-52. PMID: 35663531; PMCID: PMC9153261.
      Citations: 3     
    5. Pairawan S, Zhao M, Yuca E, Annis A, Evans K, Sutton D, Carvajal L, Ren JG, Santiago S, Guerlavais V, Akcakanat A, Tapia C, Yang F, Bose PSC, Zheng X, Dumbrava EI, Aivado M, Meric-Bernstam F. First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. Breast Cancer Res. 2021 03 04; 23(1):29. PMID: 33663585; PMCID: PMC7934277.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    6. Tapia C, Aung PP, Roy-Chowdhuri S, Xu M, Ouyang F, Alshawa A, Hajjar J, Singh G, Yang V, Castillo L, Le H, Murthy R, Stephen B, Hess KR, Wistuba I, Naing A. Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors. J Immunother Cancer. 2020 04; 8(1). PMID: 32303619; PMCID: PMC7204618.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    7. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1). PMID: 32188704; PMCID: PMC7078933.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    8. Tew BY, Legendre C, Schroeder MA, Triche T, Gooden GC, Huang Y, Butry L, Ma DJ, Johnson K, Martinez RA, Pierobon M, Petricoin EF, O'shaughnessy J, Osborne C, Tapia C, Buckley DN, Glen J, Bernstein M, Sarkaria JN, Toms SA, Salhia B. Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones. Neuro Oncol. 2020 01 11; 22(1):70-83. PMID: 31433055; PMCID: PMC6954401.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    9. Imboden S, Tapia C, Scheiwiller N, Kocbek V, Janzen J, Mueller MD, McKinnon B, Altermatt HJ. Early-stage endometrial cancer, CTNNB1 mutations, and the relation between lymphovascular space invasion and recurrence. Acta Obstet Gynecol Scand. 2020 02; 99(2):196-203. PMID: 31562818.
      Citations: 9     Fields:    Translation:Humans
    10. Creasy CA, Singh G, Tapia C, Xu M, Stephen B, Sabir S, Meric-Bernstam F, Haymaker C, Bernatchez C, Naing A, Forget MA. Exposure to anti-PD-1 causes functional differences in tumor-infiltrating lymphocytes in rare solid tumors. Eur J Immunol. 2019 12; 49(12):2245-2251. PMID: 31532833.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    11. Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, Fu S, Karp DD, Meric-Bernstam F, Naing A. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019 09 18; 7(1):253. PMID: 31533818; PMCID: PMC6751592.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    12. Owusu-Brackett N, Evans KW, Akcakanat A, Yuca E, Tapia C, Rizvi YQ, Dumbrava EI, Janku F, Meric-Bernstam F. TAK228 enhances antitumor activity of eribulin in triple negative breast cancer. Oncotarget. 2019 Aug 20; 10(49):5011-5019. PMID: 31489111; PMCID: PMC6707945.
      Citations: 3     Fields:    
    13. Adhikary S, Chakravarti D, Terranova C, Sengupta I, Maitituoheti M, Dasgupta A, Srivastava DK, Ma J, Raman AT, Tarco E, Sahin AA, Bassett R, Yang F, Tapia C, Roy S, Rai K, Das C. Atypical plant homeodomain of UBR7 functions as an H2BK120Ub ligase and breast tumor suppressor. Nat Commun. 2019 03 28; 10(1):1398. PMID: 30923315; PMCID: PMC6438984.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    14. Keene KS, King T, Hwang ES, Peng B, McGuire KP, Tapia C, Zhang H, Bae S, Nakhlis F, Klauber-Demore N, Meszoely I, Sabel MS, Willey SC, Eterovic AK, Hudis C, Wolff AC, De Los Santos J, Thompson A, Mills GB, Meric-Bernstam F. Molecular determinants of post-mastectomy breast cancer recurrence. NPJ Breast Cancer. 2018; 4:34. PMID: 30345349; PMCID: PMC6185974.
      Citations: 3     
    15. Meric-Bernstam F, Zheng X, Shariati M, Damodaran S, Wathoo C, Brusco L, Demirhan ME, Tapia C, Eterovic AK, Basho RK, Ueno NT, Janku F, Sahin A, Rodon J, Broaddus R, Kim TB, Mendelsohn J, Mills Shaw KR, Tripathy D, Mills GB, Chen K. Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. JCO Precis Oncol. 2018; 2018. PMID: 30035249; PMCID: PMC6050977.
      Citations: 19     Fields:    
    16. Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6468-6477. PMID: 29093017; PMCID: PMC5679124.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    17. Swisher SK, Wu Y, Castaneda CA, Lyons GR, Yang F, Tapia C, Wang X, Casavilca SA, Bassett R, Castillo M, Sahin A, Mittendorf EA. Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group. Ann Surg Oncol. 2016 07; 23(7):2242-8. PMID: 26965699.
      Citations: 32     Fields:    Translation:HumansCells
    18. Trippel M, Pfaltz K, Droeser RA, Cihoric N, Salhia B, Zweifel M, Tapia C, Grogg A, L?drach C. Androgen receptor status is highly conserved during tumor progression of breast cancer. BMC Cancer. 2015 Nov 09; 15:872. PMID: 26552477; PMCID: PMC4640208.
      Citations: 15     Fields:    Translation:Humans
    19. Varga Z, Cassoly E, Li Q, Oehlschlegel C, Tapia C, Lehr HA, Klingbiel D, Ruhstaller T, Th?rlimann B. Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study. PLoS One. 2015; 10(4):e0123435. PMID: 25885288; PMCID: PMC4401515.
      Citations: 18     Fields:    Translation:Humans
    20. Cihoric N, Tapia C, Aebersold DM, Klaeser B, Kr?ger K, L?ssl K. IMRT with ?8FDG-PET\CT based simultaneous integrated boost for treatment of nodal positive cervical cancer. Radiat Oncol. 2014 Mar 25; 9:83. PMID: 24661323; PMCID: PMC4014138.
      Citations: 15     Fields:    Translation:Humans
    21. Byron SA, Min E, Thal TS, Hostetter G, Watanabe AT, Azorsa DO, Little TH, Tapia C, Kim S. Negative regulation of NF-?B by the ING4 tumor suppressor in breast cancer. PLoS One. 2012; 7(10):e46823. PMID: 23056468; PMCID: PMC3464231.
      Citations: 22     Fields:    Translation:HumansCells
    22. Droeser R, Zlobec I, Kilic E, Heberer M, Spagnoli G, Oertli D, Tapia C, G?th U. Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers. BMC Cancer. 2012 Apr 03; 12:134. PMID: 22471961; PMCID: PMC3362763.
      Citations: 42     Fields:    Translation:HumansCells
    23. Ariazi EA, Cunliffe HE, Lewis-Wambi JS, Slifker MJ, Willis AL, Ramos P, Tapia C, Kim HR, Yerrum S, Sharma CG, Nicolas E, Balagurunathan Y, Ross EA, Jordan VC. Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc Natl Acad Sci U S A. 2011 Nov 22; 108(47):18879-86. PMID: 22011582; PMCID: PMC3223472.
      Citations: 83     Fields:    Translation:HumansCells
    24. Zlobec I, Schneider S, Kilic E, Bubendorf L, Kim S, Tapia C, G?th U. Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer. Hum Pathol. 2011 Jul; 42(7):983-90. PMID: 21315418; PMCID: PMC3103605.
      Citations: 17     Fields:    Translation:Humans
    25. Tapia C, Glatz K, Novotny H, Lugli A, Horcic M, Seemayer CA, Tornillo L, Terracciano L, Spichtin H, Mirlacher M, Simon R, Sauter G. Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. Mod Pathol. 2007 Feb; 20(2):192-8. PMID: 17361205.
      Citations: 19     Fields:    Translation:Humans
    26. Savic S, Wagner U, Novotny H, Grilli B, Herzog M, Barascud AD, Zlobec I, Cathomas G, Terracciano L, Feichter G, Bubendorf L, Tapia C, Sch?negg R. HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res. 2007; 9(3):R31. PMID: 17511881; PMCID: PMC1929093.
      Citations: 37     Fields:    Translation:Humans
    27. Al-Kuraya K, Novotny H, Bavi P, Siraj AK, Uddin S, Ezzat A, Sanea NA, Al-Dayel F, Al-Mana H, Sheikh SS, Mirlacher M, Tapia C, Simon R, Sauter G, Terracciano L, Tornillo L. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol. 2007 Jul; 60(7):768-72. PMID: 16882699; PMCID: PMC1995777.
      Citations: 44     Fields:    Translation:Humans
    28. Al-Kuraya K, Schraml P, Sheikh S, Amr S, Torhorst J, Tapia C, Novotny H, Spichtin H, Maurer R, Mirlacher M, Simon R, Sauter G. Predominance of high-grade pathway in breast cancer development of Middle East women. Mod Pathol. 2005 Jul; 18(7):891-7. PMID: 15803183.
      Citations: 30     Fields:    Translation:Humans
    29. Tapia C, Schraml P, Simon R, Al-Kuraya KS, Maurer R, Mirlacher M, Novotny H, Spichtin H, Mihatsch MJ, Sauter G. HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies. Int J Oncol. 2004 Dec; 25(6):1551-7. PMID: 15547690.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    30. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Zuber M, Dieterich H, Mross F, Wilber K, Simon R, Sauter G, K?chli O. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res. 2004 Dec 01; 64(23):8534-40. PMID: 15574759.
      Citations: 116     Fields:    Translation:Humans
    31. Simon R, Panussis S, Maurer R, Spichtin H, Glatz K, Tapia C, Mirlacher M, Rufle A, Torhorst J, Sauter G. KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):178-83. PMID: 14734467.
      Citations: 33     Fields:    Translation:Humans
    32. Genes and proteins of the alternative steroid backdoor pathway for dihydrotestosterone synthesis are expressed in the human ovary and seem enhanced in the polycystic ovary syndrome. Molecular and Cellular Endocrinology.
    33. Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group. Annals of Surgical Oncology. 1-7.
    34. Androgen receptor status is highly conserved during tumor progression of breast cancer. BMC Cancer. 15.
    35. Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study. PLoS One. 10.
    36. Dose escalated intensity modulated radiotherapy in the treatment of cervical cancer. Radiation Oncology. 10.
    TAPIA's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (202)
    Explore
    _
    Co-Authors (56)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _